Cancer-associated bone disease by R. Rizzoli et al.
Cancer-associated bone disease
Submitted by a.bergoend on Mon, 04/27/2015 - 09:52
Titre Cancer-associated bone disease
Type de
publication Article de revue
Auteur
Rizzoli, R [1], Body, J-J [2], Brandi, M.L. [3], Cannata-Andia, J [4], Chappard, Daniel
[5], El Maghraoui, A. [6], Glüer, C.-C. [7], Kendler, D [8], Napoli, N. [9], Papaioannou,
A [10], Pierroz, D.D. [11], Rahme, M [12], Van Poznak, C.H. [13], de Villiers, T J [14],
Fuleihan El Hajj, G. [15]
Editeur Springer











Antineoplastic Agents [16], Bone Density Conservation Agents [17], Bone Diseases
[18], Bone Neoplasms [19], Humans [20], Hypogonadism [21], Neoplasms [22],
osteoporosis [23], Osteoporotic Fractures [24], Risk Assessment [25]
Résumé en
anglais
Bone is commonly affected in cancer. Cancer-induced bone disease results from the
primary disease, or from therapies against the primary condition, causing bone
fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are
efficacious in preventing and delaying cancer-related bone disease. With evidence-
based care pathways, guidelines assist physicians in clinical decision-making. Of the
57 million deaths in 2008 worldwide, almost two thirds were due to non-
communicable diseases, led by cardiovascular diseases and cancers. Bone is a
commonly affected organ in cancer, and although the incidence of metastatic bone
disease is not well defined, it is estimated that around half of patients who die from
cancer in the USA each year have bone involvement. Furthermore, cancer-induced
bone disease can result from the primary disease itself, either due to circulating bone
resorbing substances or metastatic bone disease, such as commonly occurs with
breast, lung and prostate cancer, or from therapies administered to treat the primary
condition thus causing bone loss and fractures. Treatment-induced osteoporosis may
occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy,
chemotherapy-induced ovarian failure and androgen deprivation therapy. Tumour
skeletal-related events include pathologic fractures, spinal cord compression, surgery
and radiotherapy to bone and may or may not include hypercalcaemia of malignancy
while skeletal complication refers to pain and other symptoms. Some evidence
demonstrates the efficacy of various interventions including bone-modifying agents,
such as bisphosphonates and denosumab, in preventing or delaying cancer-related
bone disease. The latter includes treatment of patients with metastatic skeletal
lesions in general, adjuvant treatment of breast and prostate cancer in particular,
and the prevention of cancer-associated bone disease. This has led to the
development of guidelines by several societies and working groups to assist
physicians in clinical decision making, providing them with evidence-based care
pathways to prevent skeletal-related events and bone loss. The goal of this paper is to
put forth an IOF position paper addressing bone diseases and cancer and
summarizing the position papers of other organizations.
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